Earnings Call Summary | Amneal Pharmaceuticals(AMRX.US) Q1 2024 Earnings Conference
Earnings Call Summary | Amneal Pharmaceuticals(AMRX.US) Q1 2024 Earnings Conference
The following is a summary of the Amneal Pharmaceuticals, Inc. (AMRX) Q1 2024 Earnings Call Transcript:
以下是Amneal Pharmicals, Inc.（AMRX）2024年第一季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Amneal Pharmaceuticals reported a Q1 2024 revenue of $659 million, an increase of 18% over the same period last year.
The company experienced double-digit growth in all three business segments for the first time in a single quarter.
Their Q1 adjusted EBITDA amounted to $152 million, indicating a 31% growth in profits.
Generics net revenue stood at $391 million, a 14% increase attributed to the diversified product portfolio.
Amneal Pharmicals報告稱，2024年第一季度收入爲6.59億美元，比去年同期增長18％。
該公司在單個季度內首次在所有三個業務領域實現了兩位數的增長。
他們第一季度調整後的息稅折舊攤銷前利潤爲1.52億美元，表明利潤增長了31％。
仿製藥的淨收入爲3.91億美元，增長了14％，這歸因於多元化的產品組合。
Business Progress:
業務進展：
The company received approval for naloxone in the US and has established a partnership with the State of California to supply between 2 to 3 million units.
Amneal aims to accelerate growth in 2024 in the generic segment across retail, injectables, and biosimilars.
The company plans to launch more than 30 new products this year, continuing the momentum from 39 new launches in the previous year.
Expansion into injectables is ongoing to address drug shortages in healthcare facilities, while key neurology and endocrinology branded products have seen double-digit growth.
Launch plans for IPX203, an adjunct therapy for Parkinson's disease are on track for late this year, on the heels of a successful ONGENTYS launch.
They also made progress on drug shortages by tripling injectable manufacturing capacity recently and plan 2-3 505(b)(2) injectable launches annually with 15 in development.
Amneal is expanding to other geographies and collaborating to register and commercialize select products.
Plans for biosimilar launches of Prolia and XGEVA are set for 2026 while expecting Restasis launch in 2025.
The company's AvKARE business is expected to grow, but the option to monetize this business remains should the right offer present itself.
該公司在美國獲得了納洛酮的批准，並與加利福尼亞州建立了合作伙伴關係，供應200萬至300萬臺。
Amneal的目標是在2024年加速零售、注射劑和生物仿製藥等仿製藥領域的增長。
該公司計劃今年推出30多款新產品，延續去年推出的39種新產品的勢頭。
正在向注射劑領域擴張，以解決醫療機構的藥物短缺問題，而主要的神經病學和內分泌學品牌產品則實現了兩位數的增長。
繼ONGENTYS成功推出之後，帕金森氏病的輔助療法 IPX203 的發佈計劃將於今年年底啓動。
他們最近還將注射劑的生產能力提高了三倍，從而在藥品短缺問題上取得了進展，並計劃每年推出2-3505（b）（2）種注射劑，其中15種正在開發中。
Amneal正在擴展到其他地區，併合作註冊和商業化精選產品。
Prolia和XGEVA的生物仿製藥計劃於2026年上市，同時預計Restasis將於2025年上市。
該公司的AvKare業務預計將增長，但如果出現正確的報價，則仍然可以選擇通過該業務獲利。
More details: Amneal Pharmaceuticals IR
更多詳情： Amneal 製藥 IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。